Initiating insulin therapy is an important step in the management of patients with type 2 diabetes. The insulin regimen prescribed should be physiological and designed to control fasting and post-prandial glucose levels. The primary goals of therapy are achieving and maintaining tight glycemic control. The optimal insulin regimen should be patient-specific, taking the patient's lifestyle into consideration. As their diabetes progresses, an increasing number of patients require insulin therapy. An initial approach is to add basal insulin to oral hypoglycemic agents.
Progression from Basal to Pre-mixed or Rapid-acting Insulin intensively during the 10-year study period. The results of a 10-year poststudy follow-up on 3,277 of the patients remaining in the trial showed that the differences between treatment groups in terms of glycemic control were eliminated during the first year, but the risk for microvascular events and for myocardial infarction and death from any cause was reduced throughout the 10 years of post-trial follow-up. This demonstrated the long-term benefit of early glycemic control in the UKPDS population. 15 The
Epidemiology of Diabetes Interventions and Complications (EDIC) study originally compared intensive and conventional therapy in a population of 1,441 patients with type 1 diabetes. In the 17-year follow-up of this study, intensive treatment providing early glycemic control reduced the risk for any cardiovascular disease event by 42% (p=0.02 versus conventional treatment) and reduced the risk for non-fatal myocardial infarction, stroke, or death from cardiovascular disease by 57% (p=0.02).
Microalbuminuria and albuminuria were associated with a significant increase in the risk for cardiovascular disease, but differences between treatment groups remained significant (p≤0.05). It was concluded that intensive therapy has long-term beneficial effects on the risk for cardiovascular disease in patients with type 1 diabetes. 7 The level of glycemic control is gauged by fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), and glycated hemoglobin (HbA 1c ), which reflects glycemic exposure during a period of approximately three months. PPG contributes significantly to the HbA 1c value, especially as values approach target levels, 16 and post-prandial glucose excursions have recently been linked to vascular damage. 17 Control of PPG is crucial to reaching the target HbA 1c levels of 6.5% as recommended by the American Association of Clinical Endocrinologists (AACE) and <7% as recommended by the American Diabetes Association (ADA). 18, 19 Therefore, treatment with basal insulin alone may be insufficient to achieve glycemic control targets, and an intensified insulin regimen is often required to achieve target HbA 1c levels as the disease progresses.
Rationale for Early Initiation of Insulin Therapy
The Diabetes Prevention Program demonstrated that an intensive lifestyle intervention was most effective at reducing progression to diabetes in high-risk individuals, followed by metformin therapy. 20 Similarly, early intervention with insulin may potentially protect beta-cell function. 21, 22 A recent randomized, parallel-group study of 382 patients with newly diagnosed type 2 diabetes looked at the effects of intensive, short-term insulin therapy on beta-cell function. 23 Patients were randomly assigned to treatment with continuous subcutaneous insulin therapy, multiple daily injections (MDIs), or oral hypoglycemic agents. Once patients had achieved and sustained on-therapy normoglycemia for two weeks, pharmacological treatment was stopped. Normoglycemia was attained by >95% of patients in the insulin treatment groups compared with 84% of those receiving oral agents. Glycemic control, in terms of fasting blood glucose, was reached significantly faster with insulin, and at one year after treatment 51% of those who had received continuous insulin and 45% of those who had received MDIs remained normoglycemic compared with 27% of patients treated with oral hypoglycemic agents. Beta-cell function was measured at the end of therapy and after one year using homeostasis model assessment of basal beta-cell function (HOMA B) and acute insulin response. Patients treated with continuous insulin therapy had an increase in HOMA B of 160% compared with 105% for those treated with oral agents. The results of this study suggest that early insulin supplementation may protect, and possibly restore, beta-cell function, and therefore alter the progressive course of diabetes.
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Initiating Insulin Therapy
Insulin is clearly the most effective way to control hyperglycemia. There is recent evidence to suggest that healthcare providers generally wait to initiate insulin therapy and that the HbA 1c value at which they will start aggressive glucose-lowering action is 9% or higher. 23, 24 This reluctance may be due, in part, to concern about hypoglycemia and patient willingness and/or ability to inject insulin. A variety of insulin analogs are now available that lower the risk for hypoglycemia and limit weight gain.
New insulin analogs more closely mimic the kinetic profile of endogenous insulin compared with the older human insulins. Both human insulin and insulin analogs are now available in convenient pen devices that allow more flexible dosing. 25 Pens can provide more accurate dosing compared with a vial/syringe, as well as providing more discreet dosing.
They can also be easier to use/learn/teach. [26] [27] [28] In the past, a common approach to initiating insulin therapy in type 2 diabetes was to discontinue OADs and begin with a single morning dose of basal insulin. 29 for glycemic control, once-daily dosing, and less hypoglycemia. 33, 34 In addition, the new AACE guidelines recommend the use of insulin analogs over human insulin formulations. 35 The AACE recommends that treatment-naïve individuals whose initial HbA 1c value is >10% be started on insulin therapy. 19 A major challenge for primary care physicians when initiating insulin therapy is choosing when to use each of the many insulins available today; these are decreasing by 0.2% (p<0.05) among patients previously receiving NPH and by 0.6% (p<0.0001) for those who had originally received glargine. The incidence of hypoglycemia was also significantly reduced (p<0.0001). In addition, FPG decreased by 1.4mmol/l in both the NPH and glargine groups (p<0.0001). This improvement was accompanied by a weight decrease of 0.7kg (p<0.01) in those previously treated with NPH and 0.5kg (p<0.05) in patients who switched from glargine. The incidence of hypoglycemia was also reduced significantly (p<0.0001). These data provide important proof of principle that glycemic control can be improved with modern insulin analog therapy without excessive weight gain and hypoglycemia. 41 A subgroup analysis of the German cohort from the PREDICTIVE study assessed patients over a three-month period who started on OADs only (n=1,321), NPH insulin ± OADs (n=251), or insulin glargine ± OADs (n=260) and were transferred to insulin detemir with OADs. 44 After three months of insulin detemir, hypoglycemic events/patient were reduced by 84, 80, and 90%, respectively, and no major hypoglycemic events were reported.
HbA 1c and FBG were significantly reduced from baseline in each of the subgroups (p<0.0001 for both). These data were said to confirm the shortterm safety and efficacy of insulin detemir ± OADs in a real-world scenario.
These studies showed that the modern insulin therapies detemir and glargine showed improved efficacy over NPH with decreased variability and hypoglycemic events without causing excessive weight gain.
Intensification of Basal Insulin by Adding Bolus Insulin
Basal-bolus therapy with MDIs or an insulin pump is the most physiological approach to insulin therapy. When basal insulin alone in combination with an OAD fails to control hyperglycemia, addition of prandial insulin is required. Most patients will ultimately require prandial insulin in addition to basal insulin as beta-cell function declines. Basalbolus therapy using a rapid-acting insulin analog at mealtimes in addition to a basal insulin analog is highly effective and allows flexibility in both the timing and amount of prandial insulin dosing. Glycemic control can be improved with insulin analog therapy without excessive weight gain and hypoglycemia. Some patients may get by with the addition of prandial insulin only before the largest meal of the day, while others will require intensive basal-bolus therapy with prandial insulin before each meal. A potential concern for some patients is the need for multiple injections.
A common pitfall with basal insulin is increasing the dose too much before adding prandial insulin. This does not match the physiological needs, and predisposes the patient to fasting hypoglycemia without reaching the target HbA 1c level. A rule of thumb is that a patient should not be advanced to more than 0.5 units/kg bodyweight for basal insulin without first considering the addition of a rapid-acting insulin (e.g. 0.1 units/kg) with meals. 45 Insulins available for prandial coverage include regular insulin and the rapid-acting insulin analogs. The rapid-acting analogs, including aspart, lispro, and glulisine, allow closer approximation of physiological insulin secretion and also allow for flexible dosing/dosing closer to meal times. 
Intensification from Basal Insulin to Pre-mixed Insulin
Pre-mixed insulin preparations provide an alternative to basal-bolus dosing that does not involve multiple insulin preparations. Compared with pre-mixed human insulin, pre-mixed analogs may provide a glucoselowering profile that more closely mimics the physiological secretion of insulin, thus providing better glycemic control and less hypoglycemia. to be inferior to BBT on the pre-specified non-inferiority margin of 0.3%. 
Cost-effectiveness of Intensive Insulin Therapies
The aim of early initiation of insulin therapy is to prevent short-term complications, reduce long-term morbidity and mortality, and potentially alter the natural course of type 2 diabetes. Fewer complications, including hospital visits, translates to a potential decrease in the cost of healthcare.
Although optimal disease management is patient-specific, achieving and maintaining tight glycemic control are the primary goals of therapy.
Because many type 2 diabetes patients will eventually require insulin
Progression from Basal to Pre-mixed or Rapid-acting Insulin therapy, overcoming fears and therapeutic barriers to initiating therapy as early as needed is essential for reducing the vascular comorbidities of this highly prevalent disease in patients of all ages.
In an analysis of data from the PREDICTIVE study, 
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